327 related articles for article (PubMed ID: 10972684)
1. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.
Nakamura S; Nakamura I; Ma L; Vaughan DE; Fogo AB
Kidney Int; 2000 Jul; 58(1):251-9. PubMed ID: 10886570
[TBL] [Abstract][Full Text] [Related]
3. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1.
Ma LJ; Nakamura S; Aldigier JC; Rossini M; Yang H; Liang X; Nakamura I; Marcantoni C; Fogo AB
J Am Soc Nephrol; 2005 Apr; 16(4):966-76. PubMed ID: 15728787
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
[TBL] [Abstract][Full Text] [Related]
5. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.
Ma LJ; Nakamura S; Whitsitt JS; Marcantoni C; Davidson JM; Fogo AB
Kidney Int; 2000 Dec; 58(6):2425-36. PubMed ID: 11115076
[TBL] [Abstract][Full Text] [Related]
6. Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats.
Ma LJ; Jha S; Ling H; Pozzi A; Ledbetter S; Fogo AB
Kidney Int; 2004 Jan; 65(1):106-15. PubMed ID: 14675041
[TBL] [Abstract][Full Text] [Related]
7. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
[TBL] [Abstract][Full Text] [Related]
8. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
Oestreicher EM; Martinez-Vasquez D; Stone JR; Jonasson L; Roubsanthisuk W; Mukasa K; Adler GK
Circulation; 2003 Nov; 108(20):2517-23. PubMed ID: 14581407
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.
Sawathiparnich P; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2002 Feb; 87(2):448-52. PubMed ID: 11836266
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB
Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962
[TBL] [Abstract][Full Text] [Related]
11. A clinical approach in regression of glomerulosclerosis.
Stoian M; Radulian G; ChiĊ£ac D; Simion E; Stoica V
Rom J Intern Med; 2007; 45(2):215-8. PubMed ID: 18333378
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats.
Gromotowicz-Poplawska A; Stankiewicz A; Mikita J; Aleksiejczuk M; Marcinczyk N; Szemraj J; Chabielska E
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980144
[TBL] [Abstract][Full Text] [Related]
13. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats.
Hao L; Kanno Y; Fukushima R; Watanabe Y; Ishida Y; Suzuki H
Am J Nephrol; 2004; 24(1):54-60. PubMed ID: 14707436
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model.
Zhou X; Ono H; Ono Y; Frohlich ED
Am J Nephrol; 2004; 24(2):242-9. PubMed ID: 15031627
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury.
Lahmer T; Hermans R; Schmaderer C; Chang J; Stock K; Lutz J; Heemann U; Baumann M
Kidney Blood Press Res; 2012; 35(6):561-7. PubMed ID: 22890233
[TBL] [Abstract][Full Text] [Related]
16. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
Ma J; Albornoz F; Yu C; Byrne DW; Vaughan DE; Brown NJ
Hypertension; 2005 Aug; 46(2):313-20. PubMed ID: 15998706
[TBL] [Abstract][Full Text] [Related]
17. [Effect of aldosterone on the expression of plasminogen activator inhibitor-1 in renal mesangial cells: experiment with rat renal mesangial cells].
Yuan J; Jia RH; Bao Y
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2439-42. PubMed ID: 18036328
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.
Brown NJ; Kim KS; Chen YQ; Blevins LS; Nadeau JH; Meranze SG; Vaughan DE
J Clin Endocrinol Metab; 2000 Jan; 85(1):336-44. PubMed ID: 10634408
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury.
Ma J; Weisberg A; Griffin JP; Vaughan DE; Fogo AB; Brown NJ
Kidney Int; 2006 Mar; 69(6):1064-72. PubMed ID: 16528256
[TBL] [Abstract][Full Text] [Related]
20. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
